Page 47 - Read Online

Yagishita et al. J Cancer Metastasis Treat 2019;5:75 I http://dx.doi.org/10.20517/2394-4722.2019.026 Page 13 of 13

47. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, et al. Patient HLA class I genotype influences cancer response to checkpoint
blockade immunotherapy. Science 2018;359:582-7.
48. Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1
blockade in untreated metastatic melanoma. Sci Transl Med 2018;10:eaar3342.
49. Elias DJ, Hirschowitz L, Kline LE, Kroener JF, Dillman RO, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and
KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 1990;50:4154-9.
50. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, et al. Cure of xenografted human carcinomas by BR96-doxorubicin
immunoconjugates. Science 1993;261:212-5.
51. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001;13:522-7.
52. Ravandi F. Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy. J Clin Oncol 2011;29:349-51.
53. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014;6:34-45.
54. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins
(Basel) 2011;3:848-83.
55. Sehn LH, Herrera AF, Matasar MJ, Kamdar MK, McMillan A, et al. Addition of Polatuzumab Vedotin to Bendamustine and Rituximab
(BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR
alone: results from a randomized phase 2 study. Blood 2017;130:2821.
56. Deeks ED. Polatuzumab vedotin: first global approval. Drugs 2019;79:1467-75.
57. Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive
breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 2019;20:816-26.
58. Cianfriglia M. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the
experience of gemtuzumab ozogamicin. Ann Ist Super Sanita 2013;49:150-68.
59. Loganzo F, Tan X, Sung M, Jin G, Myers JS, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug
conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 2015;14:952-63.
60. Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Shimomura A, et al. First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients
(pts) with advanced folate receptor alpha (FRA)-positive solid tumors. J Clin Oncol 2019;37:5544.
61. Kim S, Song J, Park S, Ham S, Paek K, et al. Drifts in ADCC-related quality attributes of Herceptin(R): impact on development of a
trastuzumab biosimilar. MAbs 2017;9:704-14.